Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to…
PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure - Phase 1 ELIMINATE-B study successful, PBGENE-HBV Program Advancing to Phase 2- - PBGENE-HBV ach
How this was made
The 30-second read
Why it matters
The disclosed data represent the first public evidence of cccDNA elimination, a key milestone for hepatitis B cure strategies.
Market read
The breakthrough data could catalyze a re‑rating of DTIL and influence peer biotech valuations.
What to watch
Small patient cohort and lack of comparative data may limit immediate valuation impact.
Background
Precision BioSciences (NASDAQ:DTIL) uses its ARCUS platform for in‑vivo gene editing. The ELIMINATE‑B Phase 1 trial evaluated PBGENE‑HBV in 25 patients.
Ticker impact
Precision BioSciences filed an 8‑K announcing Phase 1 ELIMINATE‑B data showing 100% pgRNA loss and cccDNA reduction at the 0.4 mg/kg dose, advancing PBGENE‑HBV to Phase 2.
upside pressure as market prices in the promising trial data
First‑time disclosure of robust efficacy and safety data for a novel gene‑editing therapy typically drives a favorable price reaction.
Market effects
Strengthens the biotech gene‑editing and hepatitis‑B therapeutic subsector.
May lift US biotech indices and related ADRs.
Highlights progress in curative viral therapies, relevant to global health investors.
Counterpoint
If longer‑term safety or efficacy issues emerge, the initial hype could reverse.
Key entities
- companyPrecision BioSciences
Clinical‑stage gene‑editing biotech.
- productPBGENE‑HBV
In‑vivo gene‑editing therapy targeting hepatitis B cccDNA.
